Metastatic Colorectal CancerNCT07909122
Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer
An observational study of Metastatic Colorectal Cancer, run by Pfizer.
Trial summary
The aim of this study is to learn how doctors treat a type of metastatic colorectal cancer in everyday medical practice. The study focuses on patients whose cancer started on the left side of the colon and does not have specific gene changes called RAS mutations (this is known as RAS wild-type disease). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Metastatic Colorectal Cancer
- What is being tested?
- Anti-EGFR-Based Therapy and Anti-VEGF-Based Therapy
- How many people
- 1 participants
- Where
- No sites listed yet
- Study dates
- 30 Oct 2026to 30 Nov 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: See eligibility criteria
Who may be able to join
- Left-sided metastatic colorectal cancer RAS wild-type disease Received first-line anti-EGFR- or anti-VEGF-based therapy with chemotherapy Available follow-up in the Flatiron Health database
Who cannot join
- BRAF-mutated disease MSI-H or dMMR disease Unknown or mutant RAS status Non-left-sided primary tumor
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Real-World Treatment Patterns and Effectiveness of Anti-EGFR and Anti-VEGF-Based Therapies in Left-Sided RAS Wild-Type Metastatic Colorectal Cancer
The aim of this study is to learn how doctors treat a type of metastatic colorectal cancer in everyday medical practice. The study focuses on patients whose cancer started on the left side of the colon and does not have specific gene changes called RAS mutations (this is known as RAS wild-type disease). It will assess effectiveness of two common types of targeted treatments: anti-EGFR medicines, which block signals that help cancer cells grow, and anti-VEGF medicines, which block the growth of blood vessels that supply tumors.
This is a real-world study, not a clinical study. This means that researchers will look at what happens when patients receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information derived and de-identified from cancer clinics across the United States (from the Flatiron Health Analytic Database).
- Conditions
- Metastatic Colorectal Cancer
- Being tested
- Anti-EGFR-Based Therapy, Anti-VEGF-Based Therapy
- Keywords
- metastatic colorectal cancer, mCRC, anti-EGFR, anti-VEGF, RASwt
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Anti-EGFR-Based TherapyDrug
Patients initiating first-line anti-EGFR therapy combined with standard chemotherapy.
Anti-VEGF-Based TherapyDrug
Patients initiating first-line anti-VEGF therapy combined with standard chemotherapy.
| Study group | Role | What they receive |
|---|---|---|
| Anti-EGFR-Based Therapy Cohort | Patients initiating first-line anti-EGFR therapy combined with standard chemotherapy. Receives: Drug: Anti-EGFR-Based Therapy | |
| Anti-VEGF-Based Therapy Cohort | Patients initiating first-line anti-VEGF therapy combined with standard chemotherapy. Receives: Drug: Anti-VEGF-Based Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
First-Line Treatment Patterns
Measured: Up to approximately 13 years, 9 months
Real-World Overall Survival (rwOS)
Measured: Up to approximately 13 years, 9 months.
Secondary outcomes (2)
Treatment patterns following 1L therapy
Measured: 13 years, 9 months.
Real-world effectiveness across lines of therapy
Measured: 13 years, 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2026
- Study start30 Oct 2026 (estimated)
- Primary completion30 Nov 2027 (estimated)
- Study completion30 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metastatic Colorectal CancerStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07909122
- Sponsor's protocol ID
- C6461025
- Status last verified
- Oct 2026
- First submitted
- 26 Oct 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real-World Treatment Patterns and Effectiveness of Anti-EGFR and Anti-VEGF-Based Therapies in Left-Sided RAS Wild-Type Metastatic Colorectal Cancer
- ClinicalTrials.gov ID
- NCT07909122
- Acronym / sponsor ID
- C6461025
- Conditions
- Metastatic Colorectal Cancer
- Keywords
- metastatic colorectal cancer, mCRC, anti-EGFR, anti-VEGF, RASwt
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1 participants (estimated)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 30 Oct 2026 (estimated)
- Primary completion
- 30 Nov 2027 (estimated)
- Study completion
- 30 Nov 2027 (estimated)
- First posted
- 2 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to learn how doctors treat a type of metastatic colorectal cancer in everyday medical practice. The study focuses on patients whose cancer started on the left side of the colon and does not have specific gene changes called RAS mutations (this is known as RAS wild-type disease). It will assess effectiveness of two common types of targeted treatments: anti-EGFR medicines, which block signals that help cancer cells grow, and anti-VEGF medicines, which block the growth of blood vessels that supply tumors.
This is a real-world study, not a clinical study. This means that researchers will look at what happens when patients receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information derived and de-identified from cancer clinics across the United States (from the Flatiron Health Analytic Database).
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Anti-EGFR-Based Therapy Cohort | – | Drug: Anti-EGFR-Based TherapyPatients initiating first-line anti-EGFR therapy combined with standard chemotherapy. |
| Anti-VEGF-Based Therapy Cohort | – | Drug: Anti-VEGF-Based TherapyPatients initiating first-line anti-VEGF therapy combined with standard chemotherapy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- See eligibility criteria
Key inclusion criteria (1 listed)
- Left-sided metastatic colorectal cancer RAS wild-type disease Received first-line anti-EGFR- or anti-VEGF-based therapy with chemotherapy Available follow-up in the Flatiron Health database
Key exclusion criteria (1 listed)
- BRAF-mutated disease MSI-H or dMMR disease Unknown or mutant RAS status Non-left-sided primary tumor
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Anti-EGFR-Based TherapyPatients initiating first-line anti-EGFR therapy combined with standard chemotherapy. | Drug | Anti-EGFR-Based Therapy Cohort |
| Anti-VEGF-Based TherapyPatients initiating first-line anti-VEGF therapy combined with standard chemotherapy. | Drug | Anti-VEGF-Based Therapy Cohort |
Primary outcome
First-Line Treatment Patterns
Time frame: Up to approximately 13 years, 9 months
Real-World Overall Survival (rwOS)
Time frame: Up to approximately 13 years, 9 months.
2 secondary outcomes
Treatment patterns following 1L therapy
Time frame: 13 years, 9 months.
Real-world effectiveness across lines of therapy
Time frame: 13 years, 9 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Metastatic Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Not yet recruitingPhase 2
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Colorectal Cancer, Liver Metastases
RecruitingPhase 1
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Metastatic Solid Tumors
Not yet recruitingPhase 1/2
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
CRC
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pfizer CT.gov Call Center study director
Pfizer
Questions about this trial
What is this clinical trial studying?
An observational study of Metastatic Colorectal Cancer, run by Pfizer.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pfizer CT.gov Call Center (1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
First-Line Treatment Patterns (time frame: Up to approximately 13 years, 9 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.